Earnings Preview: Abbott Labs - Analyst Blog
April 15 2011 - 6:45AM
Zacks
Abbott
Laboratories (ABT) is all set to announce its first
quarter 2011 results on April 20, 2011 before the opening bell. The
Zacks Consensus Estimate for the first quarter of 2011 is $0.90,
representing a year-over-year increase of 11.1%. Abbott Labs has
surpassed earnings estimates consistently in the last four quarters
with a trailing four-quarter average of 1.0%.
Fourth Quarter 2010
Recap
Abbott Laboratories reported fourth
quarter earnings of $1.30 per share, a penny above the Zacks
Consensus Estimate. Earnings increased 10.2% from the year-ago
period. Higher revenues helped drive results. However, including
one-time items, earnings declined 6.1% to $0.92 per share.
Fourth quarter revenues increased
13.4% to $9.97 billion, above the Zacks Consensus Estimate of $9.89
billion.
(Read our full coverage on the
earnings report at Abbott Labs Tops 4Q Estimates.)
Agreement of Estimate
Revisions
Estimate revisions for Abbott Labs
have been scarce over the past month. Over the past thirty days,
only three analysts covering Abbott Labs have revised their
earnings estimates for the first quarter of 2011. While 2 of them
have cut their earnings estimates, 1 has moved in the opposite
direction. The annual estimates for 2011 too have not been revised
by the majority of analysts. Only 2 of the 22 analysts
following Abbott Labs for 2011 have revised their estimates
upward.
There are a number of reasons for
the downward bias regarding Abbott Labs for the first quarter of
2011. Concerns like the impact of the US health care reform,
product recalls, foreign exchange headwinds and EU pricing
austerity continue to hurt Abbott Labs. Moreover, several products
in Abbott Labs’ portfolio like Omnicef and clarithromycin are
facing declining sales due to increased generic competition.
Although sales of Abbott Labs’ lead
drug Humira (anti-inflammatory) continue to be impressive; we are
concerned about new competition in the market in the form of
Johnson and Johnson’s (JNJ) Simponi and
UCB Pharma’s (UCBJF) Cimzia. The newly invigorated
competition could lead to a slowdown in Humira’s market share
gains.
Meanwhile, Abbott’s Kaletra faces
intense competition in the HIV market from players like
Gilead Sciences (GILD), Bristol-Myers
Squibb (BMY), and Johnson and Johnson. Abbott’s lipid
franchise also faces stiff competition in the highly crowded
fenofibrate market.
Moreover, Abbott Labs faced a
regulatory setback when the development of Certriad, co-developed
with AstraZeneca (AZN), was scrapped following the
receipt of a complete response letter. This was a major
disappointment for Abbott Labs, which was looking to drive sales of
its cardiovascular franchises by launching Certriad. Such setbacks
will weigh heavily on the stock.
Magnitude of Estimate
Revisions
Estimates for the first quarter of
2011 have gone down by only $0.01 in the last 30 days due to a lack
of significant estimate revisions by the analysts following the
stock. Estimates for 2010 too are static at $4.60 over a similar
time period.
Neutral on Abbott
Labs
We currently have a Neutral
recommendation on Abbott Labs, which is supported by a Zacks #3
Rank (short-term “Hold” rating). Despite lingering challenges like
the impact of the US healthcare reform, foreign exchange headwinds
and EU pricing austerity, we believe Abbott Labs’ strong business
segments, contributions from acquisitions and late-stage pipeline
should help the company deliver strong earnings growth.
ABBOTT LABS (ABT): Free Stock Analysis Report
ASTRAZENECA PLC (AZN): Free Stock Analysis Report
BRISTOL-MYERS (BMY): Free Stock Analysis Report
GILEAD SCIENCES (GILD): Free Stock Analysis Report
JOHNSON & JOHNS (JNJ): Free Stock Analysis Report
Zacks Investment Research
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From Jun 2024 to Jul 2024
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From Jul 2023 to Jul 2024